Cosmo has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 17.1% per year.
Key information
16.94%
Earnings growth rate
17.97%
EPS growth rate
Pharmaceuticals Industry Growth
12.39%
Revenue growth rate
17.07%
Return on equity
-1.08%
Net Margin
-6.19%
Last Earnings Update
30 Jun 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cosmo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
WBAG:COPN Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 26
103
-6
30
31
31 Mar 26
103
-5
28
33
31 Dec 25
104
-4
27
34
30 Sep 25
143
28
30
36
30 Jun 25
182
60
34
39
31 Mar 25
225
97
35
39
31 Dec 24
267
133
36
40
30 Sep 24
226
96
36
39
30 Jun 24
185
59
36
38
31 Mar 24
139
24
33
33
31 Dec 23
93
-11
30
27
30 Sep 23
99
0
25
22
30 Jun 23
104
11
20
16
31 Mar 23
103
14
20
16
31 Dec 22
102
17
20
15
30 Sep 22
90
26
16
13
30 Jun 22
78
35
13
11
31 Mar 22
72
28
12
11
31 Dec 21
65
22
11
11
30 Sep 21
64
6
14
13
30 Jun 21
63
-11
17
14
31 Mar 21
62
-9
18
14
31 Dec 20
61
-8
19
14
30 Sep 20
64
-7
21
14
30 Jun 20
67
-7
24
15
31 Mar 20
65
-16
30
15
31 Dec 19
62
-24
35
15
30 Sep 19
56
-28
39
14
30 Jun 19
50
-31
42
14
31 Mar 19
58
-24
46
12
31 Dec 18
66
-18
51
10
30 Sep 18
69
-20
52
10
30 Jun 18
73
-23
54
9
31 Mar 18
70
-28
50
9
31 Dec 17
68
-32
46
9
30 Sep 17
68
-18
38
9
30 Jun 17
69
-4
31
9
31 Mar 17
69
8
23
8
31 Dec 16
68
19
16
7
30 Sep 16
70
18
13
10
30 Jun 16
72
16
10
13
31 Mar 16
66
132
16
18
31 Dec 15
61
248
23
23
30 Sep 15
60
241
26
23
Quality Earnings: COPN is currently unprofitable.
Growing Profit Margin: COPN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COPN is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare COPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: COPN has a negative Return on Equity (-1.08%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/04 04:32
End of Day Share Price
2026/08/03 00:00
Earnings
2026/06/30
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo N.V. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.